Ruboxistaurin 32 mg daily for 8 weeks did not significantly alter renal hemodynamic function compared to placebo during clamped euglycemia or hyperglycemia in patients with type 1 diabetes.
RCT (n=20)
2:1
OBJECTIVE: The aim of this study was to examine the effect of protein kinase Cbeta inhibition with ruboxistaurin on renal hemodynamic function and urinary biomarkers (monocyte chemoattractant protein-1 MCP-1 and epidermal growth factor) in renin angiotensin system blockade-treated type 1 diabetic subjects. RESEARCH DESIGN AND METHODS: Albuminuric subjects were randomized (2:1) to ruboxistaurin (32 mg daily; n = 13) or placebo (n = 7) for 8 weeks. Renal hemodynamic function was measured during clamped euglycemia or hyperglycemia and before and after ruboxistaurin or placebo. RESULTS: Ruboxistaurin was not associated with between-group differences during clamped euglycemia or hyperglycemia. In a post hoc analysis comparing hyperfilterers with normofilterers during euglycemia, glomerular filtration rate and MCP-1 decreased, whereas the epidermal growth factor-to-MCP-1 ratio increased in hyperfilterers versus normofilterers (all P < 0.05). CONCLUSIONS: The effect of ruboxistaurin is modest and dependent, at least in part, on the level of ambient glycemia and baseline glomerular filtration rate.
Cherney et al. (Thu,) conducted a rct in Type 1 diabetes with albuminuria (n=20). Ruboxistaurin vs. Placebo was evaluated on Renal hemodynamic function and urinary biomarkers (MCP-1 and epidermal growth factor). Ruboxistaurin 32 mg daily for 8 weeks did not significantly alter renal hemodynamic function compared to placebo during clamped euglycemia or hyperglycemia in patients with type 1 diabetes.